Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Biocon's breast cancer drug CANMAb to be available from Feb 2014

The drug will be available at about 25% discount to the current list price of the reference product in India

BS B2B Bureau  |  Bangalore 

Ltd has announced that (150 mg/440 mg), a for the treatment of HER2-positive metastatic breast cancer, will be available to patients around the first week of February 2014. CANMAb, developed jointly by and Mylan under a global partnership, is the world’s first version of
 
is being manufactured at Biocon’s biologics facility in Bangalore and will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.


 
According to the company, breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with
 
Kiran Mazumdar-Shaw, Chairperson & Managing Director, Ltd, said, “intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with (trastuzumab), which offers the same level of safety and efficacy as the reference product.”
 
is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient’s condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.
 
“India is witnessing increased usage of targeted therapies like biologics as compared to
cytotoxics. This trend is likely to continue given the improved treatment outcomes. The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like will make access more affordable and thereby expand the patient pool,” said the company in a press release.
 
The global sales for stood at about $ 6.4 billion in 2012, while in India it recorded sales of $ 21 million. 

RECOMMENDED FOR YOU

Biocon's breast cancer drug CANMAb to be available from Feb 2014

The drug will be available at about 25% discount to the current list price of the reference product in India

The drug will be available at about 25% discount to the current list price of the reference product in India Ltd has announced that (150 mg/440 mg), a for the treatment of HER2-positive metastatic breast cancer, will be available to patients around the first week of February 2014. CANMAb, developed jointly by and Mylan under a global partnership, is the world’s first version of
 
is being manufactured at Biocon’s biologics facility in Bangalore and will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.
 
According to the company, breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with
 
Kiran Mazumdar-Shaw, Chairperson & Managing Director, Ltd, said, “intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with (trastuzumab), which offers the same level of safety and efficacy as the reference product.”
 
is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient’s condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.
 
“India is witnessing increased usage of targeted therapies like biologics as compared to
cytotoxics. This trend is likely to continue given the improved treatment outcomes. The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like will make access more affordable and thereby expand the patient pool,” said the company in a press release.
 
The global sales for stood at about $ 6.4 billion in 2012, while in India it recorded sales of $ 21 million. 
image
Business Standard
177 22

Biocon's breast cancer drug CANMAb to be available from Feb 2014

The drug will be available at about 25% discount to the current list price of the reference product in India

Ltd has announced that (150 mg/440 mg), a for the treatment of HER2-positive metastatic breast cancer, will be available to patients around the first week of February 2014. CANMAb, developed jointly by and Mylan under a global partnership, is the world’s first version of
 
is being manufactured at Biocon’s biologics facility in Bangalore and will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.
 
According to the company, breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and will offer a high quality, more affordable option to breast cancer patients in India. Approximately, 1.5 lakh new patients are diagnosed with breast cancer every year in India, of which nearly 25% cases are HER2-positive and eligible for treatment with
 
Kiran Mazumdar-Shaw, Chairperson & Managing Director, Ltd, said, “intends to make a significant difference in the treatment paradigm for HER2-positive breast cancer in India by enhancing access to more affordable treatment with (trastuzumab), which offers the same level of safety and efficacy as the reference product.”
 
is a targeted therapy for the treatment of HER2-positive breast cancer and acts by interfering with protein production and stopping the growth of cancer cells. It is easy to administer and will be given intravenously, once every 3 weeks or on a weekly basis depending on the patient’s condition. Unlike the product currently available in the market, both 150 and 440 mg formulations of can be stored for 1 month which is an important offering for patients in India, as it will ensure that there is no under dosing or wastage of drug which is quite common today.
 
“India is witnessing increased usage of targeted therapies like biologics as compared to
cytotoxics. This trend is likely to continue given the improved treatment outcomes. The relatively higher cost of developing biologics means these drugs remain unaffordable for a large section of the population. The introduction of high quality biosimilars like will make access more affordable and thereby expand the patient pool,” said the company in a press release.
 
The global sales for stood at about $ 6.4 billion in 2012, while in India it recorded sales of $ 21 million. 

image
Business Standard
177 22